TrialsgrambetaRCTs are beautiful

ZeNix

2022

Bedaquiline-Pretomanid-Linezolid Regimens for MDR/XDR-TB

In 181 patients with MDR or XDR tuberculosis, BPaL with linezolid 600 mg for 26 weeks preserved favourable outcome while reducing toxicity compared with linezolid 1200 mg for 26 weeks.

Result

Primary endpoint: Favourable outcome at 6 months post-treatment

Favourable outcome ~91% in linezolid-600/26-wk arm; overall risk-benefit favoured this arm (less peripheral neuropathy/myelosuppression, fewer dose modifications).

Original publication
Subtopic
MDR/XDR-TB
Design
Phase 3 dose-finding RCT
Relevance
Supporting: context rather than must-know.
Source
Conradie F, et al. N Engl J Med. 2022;387(9):810-823.doi 10.1056/NEJMoa2119430

Discussion & critique

Defined the optimal linezolid dose for BPaL: preserves efficacy and protects the peripheral nervous system.

Discussed in podcasts